Yale HHT Center – is a model of success. Since its development at Yale School of Medicine in 1994, our center’s principals of care have been adopted and replicated by 27 centers worldwide. The interest in establishing additional centers is of great importance to patients and physicians, alike, but the time and resources needed to train colleagues in the Yale model remain scarce.
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder of blood vessels. Between 50,000 and 100,000 Americans are affected by HHT and most go undiagnosed. There are three types of HHT. Type 1 is caused by mutations in the endoglin gene and type 2 is caused by mutations in the ALK-1 gene, both of which encode proteins that are involved in the proper development of blood vessels.